StockNews.AI
CATX
StockNews.AI
179 days

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

1. CATX will report 2024 full-year results on March 26, 2025. Business update included. 2. Announcement details advanced 212Pb radiopharmaceutical technology in cancer therapies. 3. Phase 1/2a trials target melanoma and neuroendocrine tumors actively. 4. Expanding regional facilities using proprietary 212Pb generator for patient-ready products.

Earnings
-2.82%Current Return
VS
-1.71%S&P 500
$2.8402/21 07:07 AM EDTEvent Start
$2.7602/24 07:21 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The announcement is a scheduled earnings update, historically yielding muted immediate price reactions as actual results remain unknown.

How important is it?

While a scheduled update can trigger volatility, expectations are likely priced in, limiting impact significance.

Why Short Term?

Earnings releases typically prompt near-term price movements when investors react to the numbers, similar to past events.

Related Companies

February 21, 2025 07:00 ET  | Source: Perspective Therapeutics, Inc. SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a business update on Wednesday, March 26, 2025 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. About Perspective Therapeutics, Inc.Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are in Phase 1/2a imaging and therapy trials in the U.S. for the treatment of metastatic melanoma and neuroendocrine tumors, respectively. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at www.perspectivetherapeutics.com. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@perspectivetherapeutics.com Russo Partners, LLCNic JohnsonPerspectiveIR@russopr.com

Related News